B. Soria

A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol

A. Borobia, C. Solano, A. Carcas, 2021, Trials.

Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)

A. Borobia, C. Solano, A. Carcas, 2021, EClinicalMedicine.

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy

C. Solano, A. Balas, F. Garcia-sanchez, 2021, Frontiers in Cell and Developmental Biology.

SARS-CoV-2 specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking and large-scale production for Adoptive Cell Therapy

C. Solano, A. Balas, F. Garcia-sanchez, 2020, bioRxiv.

Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy

C. Solano, J. Vicario, M. Vesga, 2021, Immunology.

Editorial: A Compendium of Recent Research on Stem Cell-Based Therapy for Covid-19

R. Zhao, T. Smani, A. Hmadcha, 2021, Frontiers in Cell and Developmental Biology.

Rationale for combined therapies in severe-to-critical COVID-19 patients

A. Hmadcha, J. M. Sempere-Ortells, R. Goterris, 2023, Frontiers in Immunology.

Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210).

M. Díaz-Almirón, R. Goterris, R. de Paz, 2023, Cytotherapy.